Global Foot and Mouth Disease Vaccine Market, by Vaccine Type ((Conventional Vaccine [Aluminum Hydroxide based vaccines and Oil based vaccines] and Emergency Vaccines) and by Animal Type (Cattle, Swine, Goat and Sheep, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,396.3 Million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing government initiatives for carrying out maximum vaccination of animals are expected to drive the global foot and mouth disease vaccine market growth. For instance, on June 15 2022, according to data published by National Center for Biotechnology Information, the foot and mouth disease has surged to more than 151,000 cases in Indonesia. The government of Indonesia launched a vaccination program for foot and mouth disease for animals. The government of Indonesia decided to prioritize healthy animals with a high risk of infection in livestock husbandry centers and cows kept by small farmers, among others. The disease has been found in 18 of the country's 34 provinces, with the number of infected livestock growing fast from 20,000 less than a May month. The government is aiming to import 3 million doses of vaccine for the disease from producers in France, Australia, Brazil, and New Zealand, despite the agriculture minister expressing a preference for locally made vaccines, of which production is expected by the end of August 2022.
Global Foot and Mouth Disease Vaccine Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global foot and mouth disease vaccine market, owing to increasing funding for development of SARS- CoV-2 vaccine due to rise in demand of Covid-19 vaccine during pandemic period. For instance, in May 2020, Sinovac Biotech Ltd., a biopharmaceutical company had received US$15million in funding from government of China to advance the development of its Covid-19 vaccine candidate, CoronaVac. Advantech Capital and Vivo Capital have invested $7.5m each in Sinovac’s subsidiary
Global Foot and Mouth Disease Vaccine Market: Key Developments
In May 2022, according to American Society for Microbiology, originally the Society of American Bacteriologists, currently available commercial Foot and Mouth Disease vaccines contain chemically inactivated whole viruses, which are thought to be slow acting as they are effective only 4 to 7 days following vaccination. Hence, development of a novel rapid vaccine or alternative measures, such as antiviral agents or the combination of vaccines and antiviral agents for prompt FMD virus (FMDV) outbreak containment, is desirable. The American Society for Microbiology constructed a recombinant baculovirus (BacMam) expressing consensus porcine interferon alpha (IFN-α) that has three additional N-glycosylation sites driven by a cytomegalovirus immediate early (CMV-IE) promoter (Bac-Con3N IFN-α) for protein expression in mammalian cells. Bac-Con3N IFN-α expressing highly glycosylated porcine IFN-α protein increased the duration of antiviral effects. The antiviral effects of Bac-Con3N IFN-α in swine cells and mice were evaluated by the American Society for Microbiology and observed sustained antiviral effects in pig serum. Additionally, Bac-Con3N IFN-α exhibited sustained antiviral effects in vivo as well as adjuvant effects in combination with an inactivated FMD vaccine. Pigs injected with a combination of Bac-Con3N IFN-αand the inactivated FMD vaccine were protected against FMDV at 1, 3, and 7 days post vaccination. Furthermore, observed that in combination with the inactivated FMD vaccine, Bac-Con3N IFN-α increased neutralizing antibody levels in mice and pigs.
Browse 35 Market Data Tables and 30 Figures spread through 200 Pages and in-depth TOC on “Global Foot and Mouth Disease Vaccine Market”- Forecast to 2030, Global Foot and Mouth Disease Vaccine Market, by Vaccine Type ((Conventional Vaccine [Aluminum Hydroxide based vaccine, Oil based vaccines] and Emergency Vaccines) and by Animal Type (Cattle, Swine, Goat and Sheep and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Foot and Mouth Disease Vaccine Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/foot-and-mouth-disease-vaccine-market-1945
Key Takeaways of the Global Foot and Mouth Disease Vaccine Market:
- Global foot and mouth disease vaccine market is expected to exhibit a CAGR of 9.4% during the forecast period due to increasing research and development activities by key players for development of the foot and mouth disease vaccine. For instance, in March 2022, Zoetis Inc., a producer of medicine and vaccinations for pets and livestock has Center for Transboundary and Emerging Diseases (CTED) is working for developing vaccine of Conventional Vaccine type for foot and mouth disease and African swine fever. Zoetis Inc., has taken initiative to develop foot and mouth disease vaccines due to increasing demand for pork, dairy products, and meat worldwide, which requires supply of healthy animals that could be achieved through vaccination.
- Among animal type, cattle segment is expected to dominate the FMD vaccine market due to dairy products, beef, and meat demand globally. Furthermore, swine would be second most dominating animal in FMD vaccine market considering large consumption and global headcount of swine in countries such as China. For instance, in September 2020, according to an article published in ResearchGate, foot-and-mouth disease (FMD) affects domestic livestock population of India causing heavy economic losses to the animal owners. Clinical form of the disease is readily noticed in susceptible livestock population mainly cattle, buffalo and pigs but saliently maintained in carrier animals. Foot-and-mouth disease control programme (FMDCP) is run in India by adopting series of measures from clinical diagnosis of the disease in the field, to sending clinical samples for laboratory diagnosis and till selection of vaccine candidates. India ranks first in production of milk all over the world. The cattles gets infected in large number by Foot and Mouth Disease. Hence, large number are vaccines are developed for cattle.
- Asia Pacific is expected to hold a dominant position from 2017-2030 in the global foot and mouth disease vaccine market, followed by Latin America. FMD outbreak had been reported from the Asia Pacific in February 2018, especially in larger economies such as India and China, which had largest population of cattle and swine. For instance, China had biggest population of swine in the world with headcount of 433.25 million according to the Food and Agricultural Organization of United Nations in 2017.
- Major players operating in the global foot and mouth disease vaccine market include Indian Agrovet, Immunologicals Ltd., MSD Animal Health, Vallee SA, Bayer HealthCare, Brilliant Bio Pharma Ltd., Intervet, Biovet, Merial, China Animal Husbandry Co., Ltd., Biogénesis-Bagó S.A, Vetal Animal Health Products S.A.VETAL Animal Health Products, and Vecol S. A
